Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) - Total Liabilities
Based on the latest financial reports, Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) has total liabilities worth TL7.52 Billion TRY (≈ $168.49 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GENIL net assets growth trend to track the company's year-over-year net asset growth rate.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Total Liabilities Trend (2018–2024)
This chart illustrates how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's total liabilities have evolved over time, based on quarterly financial data. See GENIL cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Competitors by Total Liabilities
The table below lists competitors of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥667.46 Million |
|
RHI MAGNESITA INDIA LIMITED
NSE:RHIM
|
India | Rs13.00 Billion |
|
Controladora Vuela Compañía de Aviación S.A.B. de C.V
MX:VOLARA
|
Mexico | MX$5.45 Billion |
|
Shanghai Fortune Techgroup Co Ltd
SHE:300493
|
China | CN¥821.15 Million |
|
LX International Corp
KO:001120
|
Korea | ₩5.83 Trillion |
|
Apollo Commercial Real Estate Finance Inc
NYSE:ARI
|
USA | $8.28 Billion |
|
Central Pacific Financial Corp
NYSE:CPF
|
USA | $6.82 Billion |
|
Turk Tuborg Bira ve Malt Sanayi AS
IS:TBORG
|
Turkey | TL19.15 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GENIL company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (2018–2024)
The table below shows the annual total liabilities of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | TL5.00 Billion ≈ $112.05 Million |
+21.43% |
| 2023-12-31 | TL4.12 Billion ≈ $92.28 Million |
+369.32% |
| 2022-12-31 | TL877.88 Million ≈ $19.66 Million |
+5.11% |
| 2021-12-31 | TL835.20 Million ≈ $18.71 Million |
+60.34% |
| 2020-12-31 | TL520.88 Million ≈ $11.67 Million |
+65.49% |
| 2019-12-31 | TL314.75 Million ≈ $7.05 Million |
+4.91% |
| 2018-12-31 | TL300.03 Million ≈ $6.72 Million |
-- |
About Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV… Read more